Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 7/20 | 0.40 |
| ▸ | SMARCA2 | P51531 | 5/20 | 0.40 |
| ▸ | SMARCA4 | P51532 | 5/20 | 0.40 |
| ▸ | IKBKB | O14920 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.34 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | TAF1 | P21675 | 1/20 | 0.32 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22777062 | 0.86 | IKBKB (0.48) | PBRM1SMARCA2SMARCA4IKBKBHTR2C | |
| SCHEMBL29619417 | 0.86 | IKBKB (0.48) | PBRM1SMARCA2SMARCA4IKBKBHTR2C | |
| SCHEMBL25468683 | 0.84 | SMARCA2 (0.49) | PBRM1SMARCA2SMARCA4 | |
| SCHEMBL22777840 | 0.84 | PBRM1 (0.39) | PBRM1SMARCA2SMARCA4IKBKBHTR2C | |
| SCHEMBL24461294 | 0.80 | IKBKB (0.44) | PBRM1SMARCA2SMARCA4IKBKBHTR2C | |
| SCHEMBL22790943 | 0.78 | CYP1A2 (0.49) | PBRM1SMARCA2SMARCA4CYP1A2APP | |
| SCHEMBL22777839 | 0.77 | PBRM1 (0.41) | PBRM1SMARCA2SMARCA4NR1I2CAMKK2 | |
| SCHEMBL24461290 | 0.75 | PBRM1 (0.40) | PBRM1SMARCA2SMARCA4IKBKBNR1I2 | |
| SCHEMBL30552534 | 0.75 | PBRM1 (0.40) | PBRM1SMARCA2SMARCA4IKBKBNR1I2 | |
| SCHEMBL25467865 | 0.75 | PBRM1 (0.40) | PBRM1SMARCA2SMARCA4IKBKBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2020251972-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | PBRM1 5/4885SMARCA2 6/4885SMARCA4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.